Zeneca
Zeneca[edit]
Zeneca was a British multinational pharmaceutical company that was formed in 1993 by the demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries (ICI). Zeneca was headquartered in London, United Kingdom.
History[edit]
The formation of Zeneca was part of a strategic move by ICI to focus on its core chemicals business. Zeneca quickly established itself as a major player in the pharmaceutical industry, with a strong emphasis on research and development.
In 1999, Zeneca merged with the Swedish pharmaceutical company Astra AB to form AstraZeneca, one of the world's leading pharmaceutical companies. This merger was driven by the complementary strengths of the two companies, with Astra's expertise in gastrointestinal and cardiovascular drugs and Zeneca's strong oncology and respiratory portfolios.
Products[edit]
During its existence, Zeneca developed and marketed a range of pharmaceutical products. Some of the notable drugs included:
- Nolvadex (tamoxifen): A drug used in the treatment of breast cancer.
- Zoladex (goserelin): A medication used to treat prostate cancer and breast cancer.
- Seroquel (quetiapine): An antipsychotic used to treat schizophrenia and bipolar disorder.
Research and Development[edit]
Zeneca invested heavily in research and development, focusing on areas such as oncology, cardiovascular, and respiratory diseases. The company established several research facilities around the world, including in the United Kingdom and the United States.
Merger with Astra[edit]
The merger between Zeneca and Astra was announced in December 1998 and completed in April 1999. The new company, AstraZeneca, became one of the largest pharmaceutical companies in the world, with a strong presence in both Europe and the United States.
Legacy[edit]
Although Zeneca as a standalone company ceased to exist after the merger, its legacy continues through AstraZeneca. The merger allowed for the pooling of resources and expertise, leading to the development of new and innovative treatments for various diseases.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
